These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23047788)

  • 41. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
    Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
    Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tricyclic antidepressants (TCA) may improve atomoxetine's efficacy.
    Niederhofer H
    Int J Neuropsychopharmacol; 2008 Sep; 11(6):877. PubMed ID: 18346294
    [No Abstract]   [Full Text] [Related]  

  • 43. National antidepressant prescribing in children and adolescents with mental health disorders after an FDA boxed warning.
    Mittal M; Harrison DL; Miller MJ; Brahm NC
    Res Social Adm Pharm; 2014; 10(5):781-90. PubMed ID: 24355381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of atomoxetine and suicidal ideation in children and adolescents: Results of an observational cohort study within general practice in England.
    Davies M; Coughtrie A; Layton D; Shakir SA
    Eur Psychiatry; 2017 Jan; 39():11-16. PubMed ID: 27810613
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of non-therapeutic atomoxetine exposures--a national poison data system study.
    Monte AA; Ceschi A; Bodmer M
    Hum Psychopharmacol; 2013 Sep; 28(5):471-6. PubMed ID: 23861380
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010.
    Garfield CF; Dorsey ER; Zhu S; Huskamp HA; Conti R; Dusetzina SB; Higashi A; Perrin JM; Kornfield R; Alexander GC
    Acad Pediatr; 2012; 12(2):110-6. PubMed ID: 22326727
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.
    Bian J; Chen B; Hershman DL; Marks N; Norris L; Schulz R; Bennett CL
    J Clin Oncol; 2017 Jun; 35(17):1945-1951. PubMed ID: 28441110
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ADHD medication use following FDA risk warnings.
    Barry CL; Martin A; Busch SH
    J Ment Health Policy Econ; 2012 Sep; 15(3):119-25. PubMed ID: 23001280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
    Yu G; Li GF; Markowitz JS
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):314-26. PubMed ID: 26859445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New and incremental FDA black box warnings from 2008 to 2015.
    Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
    Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
    Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
    Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New warning about ADHD drug.
    FDA Consum; 2005; 39(2):3. PubMed ID: 16121414
    [No Abstract]   [Full Text] [Related]  

  • 53. FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.
    Cope JU; Rosenthal GL; Weinel P; Odegaard A; Murphy DM
    Pediatrics; 2015 Dec; 136(6):1125-31. PubMed ID: 26598453
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia.
    Rubino A; Sanon M; Ganz ML; Simpson A; Fenton MC; Verma S; Hartry A; Baker RA; Duffy RA; Gwin K; Fillit H
    JAMA Netw Open; 2020 Apr; 3(4):e203630. PubMed ID: 32343351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review.
    Hammerness P; McCarthy K; Mancuso E; Gendron C; Geller D
    Neuropsychiatr Dis Treat; 2009; 5():215-26. PubMed ID: 19557116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contraindicated use of cisapride: impact of food and drug administration regulatory action.
    Smalley W; Shatin D; Wysowski DK; Gurwitz J; Andrade SE; Goodman M; Chan KA; Platt R; Schech SD; Ray WA
    JAMA; 2000 Dec; 284(23):3036-9. PubMed ID: 11122591
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools.
    Sobel RE; Bate A; Marshall J; Haynes K; Selvam N; Nair V; Daniel G; Brown JS; Reynolds RF
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):332-339. PubMed ID: 29392851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Doing nothing is doing something: primary care antidepressant treatment in the era of FDA boxed warnings.
    Lacy BW; Baron DA; Goin MK; Gross LS; Slaby AE; Sumner CR
    J Am Osteopath Assoc; 2013 Feb; 113(2):117-9. PubMed ID: 23412671
    [No Abstract]   [Full Text] [Related]  

  • 59. Prospective Assessment of Inpatient Boxed Warning Prescriber Adherence.
    Kloet MA; Lohr BR; Smithburger PL; Seybert AL; Kane-Gill SL
    J Patient Saf; 2017 Mar; 13(1):25-30. PubMed ID: 24647270
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.